arrow
J

José Luís Molinuevo

pasqual maragall foundation
H指数:105
被引数:6.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Soluble Aβ pathology predicts neurodegeneration and cognitive decline independently on p-tau in the earliest Alzheimer's continuum: Evidence across two independent cohorts

可溶性Aβ病理在阿尔茨海默病连续体的最早阶段独立于p-tau预测神经退行性变和认知衰退:来自两个独立队列的证据

2025-02-030
OAAI
The CSF p-tau/β-amyloid 42 ratio correlates with brain structure and fibrillary β-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease
2024-12-130
OAAI
Association between telomere length and cognitive function among cognitively unimpaired individuals at risk of Alzheimer's disease

阿尔茨海默病认知功能正常个体端粒长度与认知功能的关系

2024-09-011
OAAI
Time-encoded ASL reveals lower cerebral blood flow in the early AD continuum
2024-07-031
OA
Revised criteria for the diagnosis and staging of Alzheimer's disease

阿尔茨海默病诊断和分期的修订标准

2024-06-288
PRE
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

阿尔茨海默病诊断和分期的修订标准: 阿尔茨海默病协会工作组

2024-06-27127
OA
The mediating role of neuroimaging-derived biological brain age in the association between risk factors for dementia and cognitive decline in middle-aged and older individuals without cognitive impairment: a cohort study
2024-04-014
OA
Association Between Years of Education and Amyloid Burden in Patients With Subjective Cognitive Decline, MCI, and Alzheimer Disease

主观认知下降,MCI和阿尔茨海默病患者的受教育年限与淀粉样蛋白负担之间的关联

2024-03-262
OAAI
Where is VALDO? VAscular Lesions Detection and segmentatiOn challenge at MICCAI 2021
2024-01-016
OA
Recruitment of pre-dementia participants: main enrollment barriers in a longitudinal amyloid-PET study

招募痴呆前参与者: 纵向淀粉样蛋白PET研究的主要招募障碍

2023-11-022
OAAI
Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression

星形胶质细胞生物标志物GFAP和YKL-40介导早期阿尔茨海默病进展

2023-09-1021
OA
Reference Data for Attentional, Executive, Linguistic, and Visual Processing Tests Obtained from Cognitively Healthy Individuals with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels
2023-07-201
OAAI